Phase 1/2 × Has results × Leukemia, Myelomonocytic, Chronic × Clear all DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2 Completed
73 enrolled 12 charts
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2 Completed
55 enrolled 19 charts
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Phase 1/2 Completed
82 enrolled 15 charts
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1/2 Terminated
2 enrolled 14 charts
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Phase 1/2 Completed
28 enrolled 8 charts
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Phase 1/2 Terminated
20 enrolled 13 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
30 enrolled 29 charts
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Phase 1/2 Completed
50 enrolled 17 charts
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase 1/2 Completed
66 enrolled 10 charts
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Phase 1/2 Completed
55 enrolled 15 charts
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Phase 1/2 Completed
113 enrolled 21 charts
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Phase 1/2 Completed
17 enrolled 14 charts
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
25 enrolled 13 charts
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Phase 1/2 Completed
37 enrolled 14 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase 1/2 Terminated
11 enrolled 11 charts
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
Phase 1/2 Completed
60 enrolled 5 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts